European Growth Companies With High Insider Ownership For September 2026
In September 2026, European markets are navigating increased inflation concerns and rising bond yields, driven by geopolitical tensions and energy price surges. Amid this backdrop, growth companies with high insider ownership can offer a unique perspective on potential resilience and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12.1% | 39.6% |
| MilDef Group (OM:MILDEF) | 10.3% | 31.1% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 58.6% |
| KebNi (OM:KEBNI B) | 12% | 103.8% |
| Gold Road International (OB:GOLDR) | 35.9% | 89.8% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 60.7% |
| CD Projekt Red (WSE:CDR) | 35.2% | 43.4% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.2% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
Below we spotlight a couple of our favorites from our exclusive screener.
Trifork Group (CPSE:TRIFOR)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Trifork Group AG offers information technology and business services across Switzerland, Denmark, the United Kingdom, the Netherlands, the United States, and internationally with a market cap of DKK1.99 billion.
Operations: The company's revenue is primarily derived from its Services segment, which accounts for €146.01 million, followed by the Products segment at €76.54 million.
Insider Ownership: 20.1%
Earnings Growth Forecast: 25.4% p.a.
Trifork Group AG demonstrates growth potential with forecasted earnings growth of 25.4% annually, surpassing the Danish market's 6.9%. Despite slower revenue growth at 7.8%, it remains above the market average and trades at a discount to its estimated fair value. The company is expanding its SAP partnership, enhancing customer experience offerings, while cautiously exploring acquisitions amid favorable pricing conditions. Recent earnings show improved profitability with net income rising significantly year-over-year, reflecting operational resilience and strategic focus.
- Click to explore a detailed breakdown of our findings in Trifork Group's earnings growth report.
- In light of our recent valuation report, it seems possible that Trifork Group is trading behind its estimated value.
Fastighets AB Trianon (OM:TRIAN B)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Fastighets AB Trianon (OM:TRIAN B) is a Swedish real estate company that owns, builds, develops, and manages residential and commercial properties, with a market cap of approximately SEK3.26 billion.
Operations: The company's revenue is derived from its residential segment, contributing SEK585.90 million, and its community/commercial segment, contributing SEK211 million.
Insider Ownership: 39.9%
Earnings Growth Forecast: 22.9% p.a.
Fastighets AB Trianon is positioned for significant growth, with earnings projected to increase 22.9% annually, outpacing the Swedish market's 7.3%. Despite trading at a substantial discount to its fair value and relative peers, revenue growth of 6.6% lags behind potential benchmarks but remains above the national average. Recent earnings revealed a slight decline in net income, yet analysts agree on a potential stock price rise of nearly 30%, indicating investor confidence amidst modest financial challenges.
- Click here to discover the nuances of Fastighets AB Trianon with our detailed analytical future growth report.
- Our valuation report unveils the possibility Fastighets AB Trianon's shares may be trading at a discount.
Newron Pharmaceuticals (SWX:NWRN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on discovering and developing novel therapies for central and peripheral nervous system diseases in Italy and the United States, with a market cap of CHF235.94 million.
Operations: The company generates revenue primarily from its Research and Development of Pharmaceutical Drugs segment, amounting to €19.13 million.
Insider Ownership: 10.1%
Earnings Growth Forecast: 50.2% p.a.
Newron Pharmaceuticals is poised for growth, with revenue expected to increase 38.2% annually, surpassing the Swiss market's 5.2% forecast. Despite negative shareholders' equity and a volatile share price, Newron is projected to achieve profitability within three years, outpacing average market growth. Recent advancements in its ENIGMA-TRS 1 Phase III study highlight potential breakthroughs in treatment-resistant schizophrenia, reinforcing its innovative approach and expanding therapeutic options with evenamide's unique mechanism of action.
- Dive into the specifics of Newron Pharmaceuticals here with our thorough growth forecast report.
- Our expertly prepared valuation report Newron Pharmaceuticals implies its share price may be lower than expected.
Make It Happen
- Unlock our comprehensive list of 212 Fast Growing European Companies With High Insider Ownership by clicking here.
- Contemplating Other Strategies? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com